These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 31128259)
1. Towards the automated economic assessment of newborn screening for rare diseases. Prieto-González D; Castilla-Rodríguez I; González E; Couce ML J Biomed Inform; 2019 Jul; 95():103216. PubMed ID: 31128259 [TBL] [Abstract][Full Text] [Related]
2. Automated generation of decision-tree models for the economic assessment of interventions for rare diseases using the RaDiOS ontology. Prieto-González D; Castilla-Rodríguez I; González E; Couce ML J Biomed Inform; 2020 Oct; 110():103563. PubMed ID: 32931923 [TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Methods and Newborn Screening Assessment. Castilla-Rodríguez I; Vallejo-Torres L; Couce ML; Valcárcel-Nazco C; Mar J; Serrano-Aguilar P Adv Exp Med Biol; 2017; 1031():267-281. PubMed ID: 29214578 [TBL] [Abstract][Full Text] [Related]
4. The Use of Economic Evaluation to Inform Newborn Screening Policy Decisions: The Washington State Experience. Grosse SD; Thompson JD; Ding Y; Glass M Milbank Q; 2016 Jun; 94(2):366-91. PubMed ID: 27265561 [TBL] [Abstract][Full Text] [Related]
5. Dangerous and expensive screening and treatment for rare childhood diseases: the case of Krabbe disease. Lantos JD Dev Disabil Res Rev; 2011; 17(1):15-8. PubMed ID: 22447750 [TBL] [Abstract][Full Text] [Related]
9. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039 [TBL] [Abstract][Full Text] [Related]
10. Leveraging Evidence-Based Public Policy and Advocacy to Advance Newborn Screening in California. Bronstein MG; Pan RJ; Dant M; Lubin B Pediatrics; 2019 Feb; 143(2):. PubMed ID: 30606745 [TBL] [Abstract][Full Text] [Related]
11. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis. Knowles R; Griebsch I; Dezateux C; Brown J; Bull C; Wren C Health Technol Assess; 2005 Nov; 9(44):1-152, iii-iv. PubMed ID: 16297355 [TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654 [TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study. Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947 [TBL] [Abstract][Full Text] [Related]
18. An ontological foundation for ocular phenotypes and rare eye diseases. Sergouniotis PI; Maxime E; Leroux D; Olry A; Thompson R; Rath A; Robinson PN; Dollfus H; Orphanet J Rare Dis; 2019 Jan; 14(1):8. PubMed ID: 30626441 [TBL] [Abstract][Full Text] [Related]
19. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160 [TBL] [Abstract][Full Text] [Related]
20. The economics of screening infants at risk of hearing impairment: an international analysis. Burke MJ; Shenton RC; Taylor MJ Int J Pediatr Otorhinolaryngol; 2012 Feb; 76(2):212-8. PubMed ID: 22129917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]